Across the patient population, 108 (75%) patients had hormone receptor positive (HR+/HER2+) tumors, whereas the remaining 35 (25%) patients had HR-negative/HER2-positive (HR−/HER2+) BC. Here, ERBB2 is linked to breast cancer.